Symbol

Quantity

Purchase Price Per Share

Total Cost 

Current Quote

Barchart Link

Stock Weekly 

News

24

IFGNF

1. Company has been around since June 2010.
2. Pick price was 1.4 and the lowest was 0.15
3. No Major News to report
4. Based on the previous performance the stock will probably move when positive news or demand for Vaccine emerges.
5. This stock is a definite keep.

25

LIFE

1. Company has been around since June 2016
2. At its hight, it sold for 320. and now it is around 3.18
3. In its history stock has been on a steady decline.
4. 100% Sell with a Strengthening short term outlook on maintaining the current direction. others also recommend a sale.

5. e 1 analysts offering 12-month price forecasts for aTyr Pharma Inc have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +120.13% increase from the last price of 3.18.

   

   Analyst Recommendations

   The current consensus among 1 polled investment analysts is to hold stock in aTyr Pharma Inc. This rating has held steady since July, when it was unchanged from a hold rating.Move your mouse over past
   months for detail

   

    

   

   aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ ComplianceGlobeNewswire – Fri Jun 28, 3:05PM CDT

    

   In July this year, this stock had 14/1 Stock Split

26

MEDIF

1. The stock has been around since Nov 2018
2. At its hight, it was valued at 4.3

3. The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction. Others also recommend a strong buy.

4.  

   .

5. Shifting Cannabis Regulations Signal New Potential for the IndustryPR Newswire – Wed Jul 17, 8:00AM CDT
6. First Time Users and Young Adults Choose Cannabis Over Cigarettes
7. MediPharm Labs Executing on International Cannabis Extracts Strategy — CFN MediaNewsfile Corp – Thu Apr 25, 7:32AM CDT
8. This stock might probably move to a higher level.

27

MJNA

1. This stock has been around since 2005,
2. At its peek in 2005 sold for 40.00 and since has been on decline.
3. 

The Barchart Technical Opinion rating is a 100% Sell with the Strongest short term outlook on maintaining the current direction.

Medical Marijuana, Inc. Subsidiary Dixie Botanicals® Announces Launch of Watermelon-Flavored CBD Gummies
Medical Marijuana, Inc. Subsidiaries HempMeds®, HempMeds® Mexico and HempMeds® Brasil Announce July 2019 as the Largest Sales Bookings Month in Company HistoryPR Newswire – Tue Aug 6, 8:00AM CDT

Medical Marijuana, Inc. Subsidiary Kannaway® Enters Strategic Partnership With Endocanna Health to Create and Sell Endocannabinoid DNA Test Products

Medical Marijuana, Inc. Begins Manufacturing Operations Under An Industrial Hemp Processor LicenseGlobeNewswire – Thu Jul 25, 8:00AM CDT

This stock might go up to break even.

28

MLNT

1. Company has been around since 2012.
2. At its height, it sold for over 1000. now it is around 3

3. The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

   The 5 analysts offering 12-month price forecasts for Melinta Therapeutics Inc have a median target of 13.00, with a high estimate of 70.00 and a low estimate of 5.00. The median estimate represents a +238.54% increase from the last price of 3.84.

   

   Analyst Recommendations

   The current consensus among 7 polled investment analysts is to buy stock in Melinta Therapeutics Inc. This rating has held steady since July, when it was unchanged from a buy rating

    

   

    

   Is a Beat in Store for Melinta (MLNT) This Earnings Season?Zacks Equity Research – Zacks Investment Research – Mon Aug 5, 9:09AM CDT

   Melinta Therapeutics, Inc. (MLNT) Dips More Than Broader Markets: What You Should KnowZacks Equity Research – Zacks Investment Research – Mon Jul 29, 4:50PM CDT

   Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual MeetingGlobeNewswire – Tue May 7, 7:03AM CDT

29

MNKD

1. This company has been around since 2004.
2. At its height in 2006 sold for 108 now, it is at its lowes 1.12
3. Barchart recommends a strong sell other recommend buy.

4. The 3 analysts offering 12-month price forecasts for MannKind Corp have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +167.86% increase from the last price of 1.12.

   

   Analyst Recommendations

   The current consensus among 3 polled investment analysts is to buy stock in MannKind Corp. This rating has held steady since July, when it was unchanged from a buy rating.Move your mouse over past
   months for detail

   

    

   

    

    

   MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform

   MannKind Repays Maturing Debt Obligation; Buys Back Certain WarrantsGlobeNewswire – Thu Jul 18, 7:52AM CDT

   MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency MoleculesGlobeNewswire – Thu Jul 11, 3:15PM CDT

   MannKind Announces Afrezza(R) Distribution Agreement in AustraliaGlobeNewswire – Thu May 16, 3:02PM CDT

   Stock seems to have potential when the price goes over 10 in the future consider a sale.

30

MRNS

1. Company has been around since Aug 2014.
2. At its peak sold for around 16 now, it is at its lowest level.
3. The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

4. The 7 analysts offering 12-month price forecasts for Marinus Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 22.00 and a low estimate of 3.00. The median estimate represents a +367.29% increase from the last price of 1.07.

   

   Analyst Recommendations

   The current consensus among 8 polled investment analysts is to buy stock in Marinus Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a buy rating.

   

Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum DepressionGlobeNewswire – Tue Jul 23, 6:30AM CDT

Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related EpilepsyGlobeNewswire – Wed Mar 6, 6:29AM CST

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire – Fri Jan 25, 2:59PM CST

31

MRSN

1. This stock has been around since June 2018.
2. At its peak sold for 21 now, it is at its lowest 2.77
3. Technicals suggest a strong sale.
4.  CNN analyst suggests a buy  and forecasts a price of 11 in the next 12 months
5. News : Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
6. Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
7. This company at this time in limbo, no major movements.

32

MYDP

1. This stock has been around since the year 2000.
2. At its height, it sold for 27 but did not last long it took a sharp dive at it’s low it was 0.017
3. Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.
4. Dougherty’s Pharmacy, Inc. Announces Agreement to Sell Prescription Files of Three Pharmacy Locations for $2.7 Million
5. This stock might have activities in the future but do not expect large gains.
6.  

33

NVAX

1. This company has been around since 1996
2. Company  High was 286 Currently at 4.07
3. Company produces Vaccines
4.  Recommendations are a BUY.
5. Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual MeetingGlobe Newswire – Thu Aug 8, 6:00AM CDT
6. Novavax Reaches Agreement with the FDA on Pivotal Phase 3 Trial Design for NanoFluGlobe Newswire – Mon Aug 5, 3:06PM CDT
7. Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFluZacks Equity Research – Zacks Investment Research – Fri Jun 28, 9:10AM CDT
8. This company produces products that when need be will turn into high demand item.
9. Based on the chart this company always bounces back to new highs
10. Recommend Keep and possible buy more stocks.